Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Analyst Upgrades and Downgrades
Several research analysts recently commented on MCRB shares. Chardan Capital decreased their target price on shares of Seres Therapeutics from $16.00 to $12.00 in a research note on Thursday, August 4th. HC Wainwright reaffirmed a "buy" rating and set a $25.00 price objective on shares of Seres Therapeutics in a research note on Wednesday, June 8th. Piper Sandler reduced their price target on Seres Therapeutics from $32.00 to $7.00 and set an "overweight" rating on the stock in a report on Monday, May 23rd. Finally, Jefferies Financial Group upgraded shares of Seres Therapeutics to a "buy" rating in a report on Wednesday, June 8th.
Seres Therapeutics Price Performance
Shares of NASDAQ:MCRB opened at $5.07 on Friday. Seres Therapeutics has a 1 year low of $2.50 and a 1 year high of $11.69. The company has a debt-to-equity ratio of 2.20, a current ratio of 2.35 and a quick ratio of 2.35. The firm has a 50-day moving average of $3.75 and a 200 day moving average of $5.37.
Insider Buying and Selling
In other Seres Therapeutics news, major shareholder Health Ltp Fund Ge Nutritional acquired 8,738,243 shares of the company's stock in a transaction that occurred on Tuesday, July 5th. The shares were bought at an average cost of $3.15 per share, with a total value of $27,525,465.45. Following the completion of the transaction, the insider now directly owns 5,875,711 shares of the company's stock, valued at approximately $18,508,489.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.20% of the stock is currently owned by company insiders.